Phase III study of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia

A phase III randomised, double-blind, placebo-controlled study evaluating idelalisib in combination with rituximab in previously treated chronic lymphocytic leukaemia patients who were not fit for chemotherapy demonstrated statistically significant improvement with acceptable safety over placebo plus rituximab in term of progression-free survival, overall response rate, lymph node response and overall survival. The benefit was observed even in heavily pretreated patients, including those with adverse genetic features. The results were presented in the Late-Breaking Abstracts Session of the 55th Annual Meeting of the American Society of Hematology in New Orleans (7-10 December, 2013). Read more here.